Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU).
A new 5-fluorouracil (5-FU) derivative, 1-hexylcarbamoyl-5-fluorouracil (HCFU), has been developed in the National Cancer Center, and its phase I study is being performed in Japan by a clinical study group involving major institutions. Its LD 50 values are nearly equal to those of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) and greater than those of 5-FU, and this compound is more effective than the latter two analogues against various experimental murine tumor systems. In the phase I study, the incidence ratio of side effects was dose dependent, and the characteristic subjective symptoms were hot sensation and pollakisuria. No hematologic or serum biochemical changes were noted.
D000368:Aged; D000818:Animals; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats
C017367:carmofur; D005472:Fluorouracil